Dr. Eric P. Kielhorn
Claim this profileProMedica Flower Hospital
Area of expertise
Nasopharyngeal Carcinoma
Eric P. Kielhorn has run 1 trial for Nasopharyngeal Carcinoma. Some of their research focus areas include:
Epstein-Barr Virus Infection
Eric P. Kielhorn has run 1 trial for Epstein-Barr Virus Infection. Some of their research focus areas include:
Affiliated Hospitals
ProMedica Flower Hospital
ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
Clinical Trials Eric P. Kielhorn is currently running
Lomustine + Standard Therapy
for Glioblastoma
This phase III trial compares the effect of adding lomustine to standard chemotherapy with temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. MGMT methylated tumors are more likely to respond to temozolomide chemotherapy. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Lomustine is a chemotherapy drug and in a class of medications called alkylating agents. It damages the cell's DNA and may kill tumor cells. Radiation therapy uses high energy x-ray photons to kill tumor cells and shrink tumors. Adding lomustine to standard chemotherapy with temozolomide and radiation therapy may shrink or stabilize glioblastoma.
Recruiting
2 awards
Phase 3
4 criteria
Hormone Therapy with or without Radiation
for Breast Cancer
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting
2 awards
Phase 3
13 criteria
More about Eric P. Kielhorn
Clinical Trial Related
3 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Eric P. Kielhorn has experience with
- Cisplatin
- Fluorouracil
- Gemcitabine Hydrochloride
- Intensity-Modulated Radiation Therapy
- Paclitaxel
- Anastrozol
Breakdown of trials Eric P. Kielhorn has run
Nasopharyngeal Carcinoma
Epstein-Barr Virus Infection
Nasopharyngeal cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Eric P. Kielhorn specialize in?
Eric P. Kielhorn focuses on Nasopharyngeal Carcinoma and Epstein-Barr Virus Infection. In particular, much of their work with Nasopharyngeal Carcinoma has involved Stage II patients, or patients who are Stage III.
Is Eric P. Kielhorn currently recruiting for clinical trials?
Yes, Eric P. Kielhorn is currently recruiting for 2 clinical trials in Sylvania Ohio. If you're interested in participating, you should apply.
Are there any treatments that Eric P. Kielhorn has studied deeply?
Yes, Eric P. Kielhorn has studied treatments such as Cisplatin, Fluorouracil, Gemcitabine Hydrochloride.
What is the best way to schedule an appointment with Eric P. Kielhorn?
Apply for one of the trials that Eric P. Kielhorn is conducting.
What is the office address of Eric P. Kielhorn?
The office of Eric P. Kielhorn is located at: ProMedica Flower Hospital, Sylvania, Ohio 43560 United States. This is the address for their practice at the ProMedica Flower Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.